Bharat Bio Triumphs in Phase III Trials of Revolutionary Oral Cholera Vaccine Hillchol | A Game Changer for India!
Bharat Biotech, based in Hyderabad, announced a significant breakthrough on Wednesday with its oral cholera vaccine, Hillchol, successfully completing Phase III clinical trials. This vaccine has demonstrated efficacy against both the Ogawa and Inaba serotypes of the cholera bacteria, showing an impressive increase in vibriocidal antibodies-68.3% for Ogawa and 69.5% for Inaba. The results indicate that Hillchol is non-inferior to existing licensed vaccines, maintaining a strong safety profile across all ages with only mild adverse events reported.
The findings, published in the ScienceDirect vaccine journal, stem from a comprehensive double-blind, randomized trial that involved 1,800 participants, ranging from infants to adults, across ten clinical sites in India. Participants were divided into three age groups-adults over 18, children aged 5 to under 18, and infants aged 1 to under 5. They were randomly assigned in a 3:1 ratio to receive either Hillchol or a comparator vaccine, Shanchol.
Dr. Krishna Ella, executive chairman of Bharat Biotech, highlighted the potential impact of Hillchol in addressing the global cholera crisis and vaccine shortages. He emphasized that this new-generation oral cholera vaccine utilizes a simplified single stable O1 Hikojima strain, enhancing production efficiency and affordability, which is vital for lower- and middle-income countries. Bharat Biotech’s facilities in Hyderabad and Bhubaneswar are capable of producing 200 million doses of Hillchol annually, which could help alleviate the current global demand for cholera vaccines, estimated at 100 million doses per year versus a singular manufacturer supply.
Cholera remains a significant public health threat, causing over 2.86 million cases and approximately 95,000 deaths worldwide each year due to ingested food or water contaminated with the Vibrio cholerae bacteria. Given that Bharat Biotech has a strong portfolio-having delivered over nine billion doses globally, holding more than 145 global patents, and with registrations in over 125 countries-the development of Hillchol adds to its notable vaccine offerings.
In addition to Hillchol, Bharat Biotech has previously developed Covaxin, India’s first indigenous COVID-19 vaccine, alongside vaccines targeting diseases like influenza H1N1, rotavirus, Japanese Encephalitis (Jenvac), rabies, chikungunya, Zika, and pioneering a tetanus-toxoid conjugated vaccine for typhoid.
As vaccination campaigns continue to be crucial in combatting infectious diseases, the release of Hillchol marks a promising advancement in public health efforts, particularly for vulnerable populations in regions frequently impacted by cholera outbreaks. Bharat Biotech’s commitment to innovation and accessibility positions it as a leader in the global vaccination landscape, poised to make a substantial difference in the fight against cholera and other infectious diseases.
This development not only reflects Bharat Biotech’s dedication to addressing pressing health challenges but also underscores the importance of advancing vaccine production capabilities to meet growing global needs.
Original Source: https://timesofindia.indiatimes.com/india/bharat-bio-successfully-completes-phase-iii-trials-of-new-oral-cholera-vaccine-hillchol/articleshow/121322323.cms
Category :
Tags:
Publish Date: 2025-05-21 23:03:00
